Novo Nordisk’s Strategic Offensive: A Price War in Weight-Loss Drugs

Novo Nordisk is launching a counteroffensive in the fiercely competitive market for weight-loss medications. The Danish pharmaceutical giant is applying pressure to its main rival, Eli Lilly, by introducing an oral version of Wegovy in the United States, backed by a notably aggressive pricing strategy. Investors are interpreting this move as a significant signal of strength following a period of recent turbulence for the company.

Central to the recent positive share price movement is Novo Nordisk's pricing approach, designed to rapidly capture market share. To directly challenge Eli Lilly's competing product, Zepbound, the company is offering the introductory dose of its daily tablet for $149 per month to cash-paying customers. This promotional price is available until mid-April 2026.

This cost stands in stark contrast to the typical expense for injectable GLP-1 agonists, which frequently exceed $1,000 per month for patients without insurance coverage. The oral medication is now available at more than 70,000 U.S. pharmacies, including major chains such as CVS and Costco. The launch is further supported by integration with digital health platforms to streamline the prescription process.

Rebuilding Momentum After Setbacks

The market introduction arrives at a critical juncture for Novo Nordisk. It is bolstered by Phase 3 clinical trial data from the OASIS 4 study, which demonstrated an average weight reduction of 14% over a 64-week period. This positive development helps offset recent disappointment from the failed EVOKE Alzheimer's study in December, which had previously weighed on the stock.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Concurrently, the firm is undergoing internal restructuring, including the departure of its U.S. communications head, Jennifer Duck, as part of a global reorganization. The market's positive reaction despite this executive change underscores that investor focus is currently fixed almost exclusively on the commercial potential of the new tablet.

Wall Street's Renewed Confidence

The strategic offensive is brightening sentiment on Wall Street. J.P. Morgan analyst Richard Vosser reaffirmed his "Buy" rating for Novo Nordisk shares this week. This confidence is mirrored in the equity's performance: the stock has advanced approximately 9.5% over a seven-day period, recently trading around €48. While this represents a meaningful recovery from its 52-week low of €39.05, the share price remains distant from its previous highs.

The first half of 2026 is now expected to be largely defined by how swiftly the tablet gains traction in the cash-pay segment. Novo Nordisk has secured a strategic timing advantage, as Eli Lilly's own oral competitor, Orforglipron, remains in development and is not anticipated to seek regulatory approval until later this year. The sustainability of the share price recovery will ultimately hinge on prescription data trends in the coming weeks.